Investigating how a specific platelet receptor contributes to blood clot formation in arteries
Platelet CLEC-2 in Arterial Thrombosis
This study is looking at how a specific receptor on platelets, called CLEC-2, helps with blood clot formation in arteries, especially for people with heart issues, to find new ways to prevent harmful clots while keeping normal clotting intact.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma Medical Research Foundation NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10652286 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the CLEC-2 receptor on platelets in the formation of blood clots within arteries, particularly in conditions like ischemic heart disease. By examining how CLEC-2 interacts with other proteins and the vessel wall under high blood flow, the study aims to identify mechanisms that could lead to new treatments for arterial thrombosis. The approach involves both laboratory experiments and analysis of platelet behavior in various conditions to uncover insights that could improve patient care. The ultimate goal is to differentiate between the processes of normal blood clotting and those that lead to harmful clots.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for arterial thrombotic diseases, such as those with a history of heart disease or stroke.
Not a fit: Patients who do not have any history of arterial thrombotic diseases or related risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent arterial thrombosis without the severe bleeding risks associated with current treatments.
How similar studies have performed: Previous studies have shown promising results in understanding platelet mechanisms in thrombosis, indicating that this research builds on established findings rather than being entirely novel.
Where this research is happening
Oklahoma City, United States
- Oklahoma Medical Research Foundation — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Xia, Lijun — Oklahoma Medical Research Foundation
- Study coordinator: Xia, Lijun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.